pyrroles has been researched along with eplerenone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Laustsen, G; Wimmett, L | 1 |
| Holman, JR; Jamieson, B; Lin, V | 1 |
| Aoki, K; Arai, K; Homma, T; Ishikawa, H; Mizuno, M; Morikawa, Y; Sada, T; Tsuruoka, H; Ubukata, N | 1 |
| Ito, S; Itoh, H; Okuda, Y; Rakugi, H; Yamakawa, S; Yoshimura, M | 1 |
| Matsushima, M; Okamura, K; Okuda, T; Shirai, K; Takamiya, Y; Urata, H; Yamamoto, F | 1 |
| Aoki, K; Asoh, Y; Hanzawa, H; Hayashi, N; Homma, T; Honzumi, M; Saito, K; Takahashi, M; Tsuruoka, H; Ubukata, O | 1 |
| Adler, GK; Baudrand, R; Brooks, D; Garza, AE; Katayama Rangel, IA; Moize, B; Pojoga, LH; Ranjit, S; Romero, JR; Treesaranuwattana, T; Trefts, E; Williams, GH; Yao, TM | 1 |
| Ito, S; Itoh, H; Kario, K; Okuda, Y; Rakugi, H; Yamakawa, S; Yoshimura, M | 1 |
| Chang, Y; Gao, X; Han, Y; Hao, J; Liang, L; Qiang, P; Shimosawa, T; Xian, Y; Xiong, Y; Xu, Q; Yang, F | 1 |
2 review(s) available for pyrroles and eplerenone
| Article | Year |
|---|---|
2004 drug approval highlights: FDA update.
Topics: Administration, Cutaneous; Amlodipine; Anti-Bacterial Agents; Antidepressive Agents; Bronchodilator Agents; Cardiovascular Agents; Drug Approval; Drug Combinations; Duloxetine Hydrochloride; Eplerenone; Estradiol; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Agents; Heptanoic Acids; Humans; Ketolides; Male; Memantine; Osteoporosis, Postmenopausal; Pyrroles; Rifamycins; Rifaximin; Scopolamine Derivatives; Spironolactone; Thiophenes; Tiotropium Bromide; United States | 2005 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Spironolactone; Ticlopidine | 2010 |
2 trial(s) available for pyrroles and eplerenone
| Article | Year |
|---|---|
Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Eplerenone; Essential Hypertension; Female; Humans; Male; Middle Aged; Pyrroles; Sulfones; Treatment Outcome | 2020 |
Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
Topics: Aged; Blood Pressure; Circadian Rhythm; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones; Treatment Outcome | 2021 |
5 other study(ies) available for pyrroles and eplerenone
| Article | Year |
|---|---|
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Topics: Administration, Oral; Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Binding, Competitive; Blood Pressure; Desoxycorticosterone Acetate; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Female; HEK293 Cells; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Protein Binding; Pyrroles; Rabbits; Radioligand Assay; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Spironolactone; Sulfones; Transcriptional Activation; Transfection; Urological Agents; Water-Electrolyte Balance | 2015 |
A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Topics: Eplerenone; Humans; Hyperaldosteronism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pyrroles; Renin; Renin-Angiotensin System; Sulfones | 2020 |
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
Topics: Amino Acid Sequence; Crystallography, X-Ray; Eplerenone; Humans; Ligands; Mineralocorticoid Receptor Antagonists; Models, Molecular; Protein Domains; Pyrroles; Receptors, Mineralocorticoid; Spironolactone; Substrate Specificity; Sulfones | 2020 |
Striatin heterozygous mice are more sensitive to aldosterone-induced injury.
Topics: Aldosterone; Animals; Blood Pressure; Calmodulin-Binding Proteins; Eplerenone; Kidney; Male; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Nerve Tissue Proteins; NG-Nitroarginine Methyl Ester; Pyrroles; Spironolactone; Sulfones | 2020 |
Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone.
Topics: Aldosterone; Animals; Eplerenone; Fibrosis; Macrophages; Mice; Myofibroblasts; Pyrroles; Rats; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Sulfones; Transforming Growth Factor beta1 | 2022 |